ATP5F1 — ATP Synthase F1 Subunit Beta

📖 Wiki Page

gene4040 wordssynced 2026-04-02

ATP5F1 — ATP Synthase F1 Subunit Beta

<table class="infobox infobox-gene">
<tr><th class="infobox-header" colspan="2">ATP5F1 — ATP Synthase F1 Subunit Beta</th></tr>
<tr><td class="label">Symbol</td><td><strong>ATP5F1</strong></td></tr>
<tr><td class="label">Full Name</td><td>ATP Synthase F1 Subunit Beta</td></tr>
<tr><td class="label">Chromosome</td><td>1p13.3</td></tr>
<tr><td class="label">NCBI Gene</td><td><a href="https://www.ncbi.nlm.nih.gov/gene/547" target="_blank">547</a></td></tr>
<tr><td class="label">Ensembl</td><td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067715" target="_blank">ENSG00000067715</a></td></tr>
<tr><td class="label">UniProt</td><td><a href="https://www.uniprot.org/uniprot/P06576" target="_blank">P06576</a></td></tr>
<tr><td class="label">Diseases</td><td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease)</td></tr>
<tr><td class="label">Expression</td><td>Brain, Heart, Muscle</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/huntington" style="color:#ef9a9a">Huntington</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">21 edges</a></td>
</tr>
</table>

ATP5F1 — ATP Synthase F1 Subunit Beta

Pathway / Mechanism Diagram

...

ATP5F1 — ATP Synthase F1 Subunit Beta

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

ATP5F1 (ATP Synthase F1 Subunit Beta) encodes the beta subunit of the F1 catalytic sector of mitochondrial ATP synthase, also known as Complex V of the electron transport chain[@nature2010]. This gene is located on chromosome 1p13.3 and is essential for oxidative phosphorylation in all eukaryotic cells, with particularly critical functions in high-energy demanding tissues including the brain[@dimauro2003]. The beta subunit provides the primary catalytic sites for ATP synthesis, making ATP5F1 fundamental to cellular energy metabolism and neuronal function[@lin2006]. PMID: 39475571

Mitochondrial ATP synthase is one of the most abundant proteins in the mitochondrial inner membrane and represents the final enzyme in the oxidative phosphorylation pathway[@schapira2006]. The enzyme catalyzes the synthesis of ATP from ADP and inorganic phosphate (Pi) using the proton gradient generated by the electron transport chain. This process is essential for maintaining cellular energy homeostasis, and its dysfunction is implicated in numerous neurodegenerative diseases[@wallace2005]. PMID: 29874566

Molecular Mechanism of ATP Synthesis

The Binding Change Mechanism

The ATP5F1 beta subunit operates through the binding change mechanism, first proposed by Paul Boyer in 1997[@boyer1993]. This model describes how the three beta subunits undergo conformational changes during the catalytic cycle, transitioning between three distinct states: Open (E), Loose (L), and Tight (T)[@abrahams1994]. The rotation of the central gamma subunit drives these conformational changes, allowing each beta subunit to sequentially bind substrates, undergo conformational change, and release ATP[@allison1998]. PMID: 33233502

The binding change mechanism requires three catalytic sites working in concert, with each site undergoing a coordinated cycle of approximately 120 degrees out of phase with the others[@weber2001]. This ensures that at any given time, one beta subunit is binding ADP and Pi, one is catalyzing ATP synthesis, and one is releasing the newly synthesized ATP[@capaldi1994]. The energy required for ATP release from the tight conformation comes from the proton gradient rather than the chemical energy of the reaction itself[@boyer1999]. PMID: 26250687

Rotary Catalysis and Energy Coupling

The coupling between proton translocation through the F0 sector and ATP synthesis in the F1 sector occurs through a rotary mechanism[@junge2000]. The central stalk, composed of the gamma and epsilon subunits, rotates within the alpha3beta3 hexamer of the F1 sector, transmitting mechanical energy to the catalytic beta subunits[@noji1997]. This rotation is driven by the protonmotive force generated by electron transport, with approximately 10 protons required to complete one full 360-degree rotation and synthesize three ATP molecules[@vik1994].

The efficiency of this coupling is critical for normal cellular function. Uncoupling proteins can dissipate the proton gradient, reducing ATP synthesis efficiency and increasing heat production[@brand2011]. However, in neurodegenerative diseases, pathological uncoupling often occurs through mitochondrial permeability transition pore (mPTP) opening or other mechanisms that dissipate the membrane potential without ATP synthesis[@bernardi2001].

Structure of the ATP5F1 Protein

The ATP5F1 protein consists of 511 amino acids forming a globular domain that sits atop the central stalk[@uniprot2026]. The protein contains six tandem beta/alpha repeats, each approximately 50 amino acids in length, arranged in a circular pattern to form the catalytic hexamer[@bianchet1998]. Each beta subunit contains three nucleotide-binding sites located at the interfaces between adjacent beta/alpha repeats[@kagawa2004].

The three catalytic sites in the ATP5F1 beta subunits have different affinities for nucleotides and different catalytic activities[@zhou1993]. The first site binds ADP and Pi with low affinity but facilitates their correct positioning for catalysis. The second site undergoes the conformational change that catalyzes ATP synthesis. The third site has high affinity for ATP and facilitates its release[@walker1982]. This asymmetry is essential for the coordinated binding change mechanism[@boyer1997].

Function in Brain Mitochondria

Mitochondrial Localization and Structure

The ATP5F1 protein localizes to the mitochondrial inner membrane where it assembles with other subunits to form the F1F0 ATP synthase complex[@bossywetzel2003]. In brain mitochondria, ATP5F1 is expressed at high levels due to the extraordinary energy demands of neuronal cells. The protein consists of 511 amino acids with a molecular weight of approximately 51 kDa and features six tandem beta/alpha repeats that form the nucleotide-binding domains[@van2009].

The F1 sector, containing three ATP5F1 beta subunits alternating with three alpha subunits, protrudes into the mitochondrial matrix and contains the catalytic sites for ATP synthesis[@zhou2010]. Each beta subunit can bind ADP, ATP, or Pi, and the conformational changes during the rotary catalytic cycle drive ATP production. The rotation of the gamma subunit within the F1 hexamer transmits mechanical energy to the beta subunits, facilitating the transition between open, loose, and tight conformations necessary for catalysis[@kann2015].

Expression in Different Brain Cell Types

ATP5F1 expression varies across different neuronal and glial cell types in the brain. [Neurons](/entities/neurons) exhibit particularly high expression due to their constant energy requirements for maintaining membrane potentials, neurotransmitter release, and synaptic plasticity[@allaman2011]. [Astrocytes](/entities/astrocytes) also express ATP5F1 but at levels reflecting their different metabolic priorities, with greater reliance on glycolysis compared to neurons[@sheng2012].

The mitochondrial density in neuronal processes, particularly at synapses, requires precise regulation of ATP5F1 function to meet localized energy demands[@devine2018]. Synaptic terminals contain high concentrations of mitochondria, and ATP5F1-mediated ATP production is essential for synaptic vesicle recycling, ion channel function, and neurotransmitter release[@kann2007].

Role in Neuronal Energy Metabolism

Oxidative Phosphorylation in Neurons

Neurons rely heavily on oxidative phosphorylation for ATP production, making ATP5F1 function critical for neuronal survival[@bolanos2010]. Unlike other cell types that can shift to glycolysis under metabolic stress, neurons have limited metabolic flexibility and require continuous mitochondrial ATP synthesis[@harris2012]. The high surface-to-volume ratio of neuronal processes further increases the demand for localized ATP production via ATP5F1[@rangaraju2014].

The ATP generated by ATP5F1 supports numerous neuronal functions including:

Maintenance of resting membrane potential via Na+/K+ ATPase
Synaptic vesicle cycling and neurotransmitter release
Calcium homeostasis and signaling
Cytoskeletal dynamics and axonal transport
Gene transcription and protein synthesis at synapses[@mnatsakanyan2020]

Coupling Efficiency and Proton Gradient

ATP5F1 function depends on the proper coupling between the proton gradient (ΔμH+) across the mitochondrial inner membrane and the catalytic cycle[@zhou2017]. Under normal conditions, the protonmotive force generated by complex I, III, and IV drives proton flow through the F0 sector of ATP synthase, causing rotation of the central stalk and ATP synthesis in the F1 sector[@hinkle2005]. This tight coupling ensures efficient ATP production with approximately 2.5-3 ATP molecules produced per NADH and 1.5-2 ATP per FADH2[@brown1995].

However, under certain pathophysiological conditions, ATP synthase can operate in reverse, hydrolyzing ATP to pump protons and maintain the mitochondrial membrane potential[@nicholls2008]. This reverse operation is particularly relevant in neurodegenerative diseases where electron transport chain dysfunction leads to membrane potential collapse[@baughman2011].

Calcium and Energy Metabolism

Neuronal activity leads to transient increases in cytosolic calcium, which is taken up by mitochondria through the mitochondrial calcium uniporter (MCU)[@mccormack1990]. Calcium uptake stimulates TCA cycle activity, increasing NADH production and enhancing the proton gradient that drives ATP synthesis by ATP5F1[@duchen2000]. This coupling between neuronal activity, calcium signaling, and ATP production ensures that energy supply matches demand at active synapses[@crompton1999].

However, excessive calcium uptake can overwhelm mitochondrial capacity, leading to mitochondrial permeability transition pore (mPTP) opening and cell death[@bernardi2015]. ATP5F1 plays a critical role in this process, as the opening of mPTP dissipates the proton gradient and uncouples ATP synthesis, converting ATP synthase to an ATP-hydrolyzing enzyme that accelerates ATP depletion[@ebanks2022].

Post-Translational Modifications

Phosphorylation

ATP5F1 is subject to phosphorylation at multiple residues, which modulates its activity and assembly[@kim2008]. Tyrosine phosphorylation has been reported in response to growth factor signaling, potentially linking cellular mitogenic signals to mitochondrial energy metabolism[@wu2007]. Serine and threonine phosphorylation events have also been documented, though their functional significance in neurons remains an active area of research[@hopper2006].

The phosphorylation status of ATP5F1 affects its catalytic activity and interactions with other subunits[@hojlund2009]. In pathological states, altered phosphorylation patterns may contribute to mitochondrial dysfunction in neurodegenerative diseases[@zhao2011]. Understanding these modifications could reveal therapeutic targets for maintaining ATP5F1 function[@deng2008].

Acetylation and SIRT3

SIRT3, a mitochondrial deacetylase, regulates ATP5F1 function through lysine deacetylation[@hirschey2010]. Under basal conditions, ATP5F1 is acetylated at multiple lysine residues, which can inhibit its catalytic activity[@lombard2007]. SIRT3-mediated deacetylation enhances ATP synthase activity and improves mitochondrial respiration[@someya2010].

This regulation is particularly relevant in the brain because SIRT3 expression is highest in neurons and is protective against oxidative stress[@hirschey2011]. The SIRT3-ATP5F1 axis represents an important link between cellular metabolic status and mitochondrial function in neurodegeneration[@van2017].

Oxidative Modifications

[Reactive oxygen species](/entities/reactive-oxygen-species) (ROS) generated during normal mitochondrial respiration can modify ATP5F1 residues, affecting enzyme function[@chen2017]. Carbonylation of critical residues, nitration of tyrosine residues, and oxidation of cysteine and methionine all impair ATP synthase activity[@murphy2009]. These modifications accumulate with age and are accelerated in neurodegenerative diseases[@federico2012].

The susceptibility of ATP5F1 to oxidative damage makes it a sensitive indicator of mitochondrial oxidative stress[@manczak2006]. Measuring ATP5F1 oxidative modifications could serve as a biomarker for neuronal injury in AD and PD[@reddy2009].

Dysfunction in Alzheimer's Disease

Reduced ATP5F1 Expression and Activity

Multiple studies have documented reduced ATP5F1 expression and activity in [Alzheimer's disease](/diseases/alzheimers-disease) (AD) brains[@manczak2004]. Post-mortem analysis of AD patient brain tissue reveals decreased ATP synthase beta subunit levels in the [hippocampus](/brain-regions/hippocampus) and cerebral [cortex](/brain-regions/cortex), regions particularly vulnerable to AD pathology[@swerdlow2014]. This reduction contributes to the well-documented neuronal energy deficit in AD and may represent a primary pathogenic mechanism rather than simply a downstream effect[@fang2020].

The decrease in ATP5F1 function in AD involves multiple mechanisms including:

Reduced gene expression and protein synthesis
Increased protein degradation
Oxidative modifications of the ATP5F1 protein
Disruption of ATP synthase assembly[@sultana2016]

Oxidative Stress and ATP5F1

Oxidative stress is an early feature of AD pathogenesis and directly targets ATP5F1[@chen2006]. Reactive oxygen species (ROS) produced by mitochondria and other sources modify ATP5F1 residues, impairing catalytic function and reducing ATP synthesis efficiency[@reed2008]. These oxidative modifications include carbonylation, nitration, and oxidation of critical cysteine and methionine residues[@kim2000].

A landmark study demonstrated that ATP synthase is a primary target of oxidative stress in AD brain, with specific modifications to the beta subunit affecting enzyme kinetics[@selkoe2002]. The resulting ATP deficit exacerbates neuronal vulnerability and contributes to synaptic loss, a correlate of cognitive decline in AD[@reddy2008].

Relationship with Amyloid-Beta and Tau

[Amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides, the hallmark aggregating proteins in AD, directly impair mitochondrial function including ATP5F1 activity[@aleardi2005]. Aβ accumulates in mitochondrial membranes and interacts with ATP synthase, reducing coupling efficiency and increasing ROS production[@wang2009]. This creates a vicious cycle where Aβ-induced mitochondrial dysfunction leads to further oxidative stress and more Aβ production[@cheng2018].

[Tau](/proteins/tau) pathology also affects ATP5F1 function through multiple mechanisms. Hyperphosphorylated tau accumulates in mitochondria and disrupts protein import, affecting ATP5F1 assembly and turnover[@du2012]. Additionally, tau pathology is associated with mitochondrial dynamics abnormalities that reduce the efficiency of ATP production[@schapira1990].

Dysfunction in Parkinson's Disease

Mitochondrial Complex I and ATP Synthase

[Parkinson's disease](/diseases/parkinsons-disease-disease) (PD) is strongly associated with mitochondrial dysfunction, particularly affecting complex I of the electron transport chain[@keeney2004]. While ATP synthase (Complex V) has received less attention, evidence indicates that ATP5F1 function is also impaired in PD[@exner2012]. The reduction in complex I activity decreases the proton gradient, limiting the substrate for ATP synthase and reducing ATP production efficiency[@van2018].

Studies of PD patient brains and animal models reveal decreased ATP5F1 expression and activity in the substantia nigra, the brain region most vulnerable to dopaminergic neuron loss[@surmeier2010]. This deficit contributes to the energy crisis in dopaminergic neurons, which have particularly high energy demands due to their autonomous pacemaking activity[@devi2009].

Alpha-Synuclein and Mitochondrial Function

[Alpha-synuclein](/proteins/alpha-synuclein), the protein that aggregates in Lewy bodies in PD, directly impacts mitochondrial function including ATP5F1[@liu2009]. Mutant alpha-synuclein accumulates in mitochondria and interacts with ATP synthase, impairing its activity and reducing ATP production[@poehler2014]. This interaction is particularly relevant given the critical role of ATP5F1 in neuronal energy metabolism[@ryan2015].

Additionally, alpha-synuclein aggregation disrupts mitochondrial dynamics, affecting the distribution and quality control of mitochondria in neuronal processes[@bellucci2012]. This leads to impaired ATP supply at synapses and nerve terminals, contributing to synaptic dysfunction that precedes overt neurodegeneration[@pissadaki2007].

Energy Crisis in Dopaminergic Neurons

Dopaminergic neurons of the substantia nigra pars compacta have exceptionally high energy requirements due to their sustained pacemaking activity and extensive axonal arborization[@surmeier2013]. This makes them particularly vulnerable to ATP5F1 dysfunction, as even modest reductions in ATP production can have severe consequences[@grunewald2019]. The energy crisis in PD involves:

Reduced ATP synthesis efficiency
Increased ATP demand due to calcium handling
Impaired mitochondrial quality control
Compensatory increases in glycolysis that are insufficient[@onyango2016]

Therapeutic Approaches

Small Molecule Activators

Several small molecule approaches target ATP5F1 function to treat neurodegenerative diseases[@cocco2019]. compounds that enhance ATP synthase assembly or stabilize the enzyme complex have shown promise in cellular and animal models[@mattson2008]. These include:

Coenzyme Q10 and analogs: Improve electron flow to Complex III, enhancing the proton gradient that drives ATP5F1[@beal1997]
ATP synthase stabilizers: Direct binding to maintain proper enzyme conformation[@liu2008]
SIRT3 activators: Enhance deacetylation and activation of ATP5F1[@someya2009]

Gene Therapy Approaches

Gene therapy strategies to increase ATP5F1 expression are being explored for neurodegenerative diseases[@chaturvedi2008]. Viral vector delivery of ATP5F1 to the brain could potentially restore mitochondrial function in affected neurons[@van2009a]. However, challenges include achieving appropriate expression levels and avoiding overexpression that could disrupt cellular energy regulation[@knott2008].

Mitochondrial Protection Strategies

Protecting mitochondria from oxidative damage preserves ATP5F1 function[@armstrong2006]. Antioxidant therapies, including mitochondria-targeted antioxidants like MitoQ, have shown benefit in preclinical models[@orsucci2010]. These compounds accumulate in mitochondria and neutralize ROS before they can damage ATP5F1 and other critical proteins[@moreira2010].

Biomarkers

ATP5F1 as a Biomarker

ATP5F1 levels in cerebrospinal fluid (CSF) and blood may serve as biomarkers for neurodegeneration[@zhang2015]. Reduced ATP5F1 in brain tissue is reflected in circulating mitochondrial DNA and proteins[@gawedawalerych2010]. Studies have shown that:

ATP5F1 autoantibodies are elevated in some AD patients[@bi2014]
Mitochondrial ATP synthase subunits are decreased in AD CSF[@schon2007]
Peripheral blood mononuclear cell ATP5F1 correlates with disease severity[@lake2016]

Therapeutic Monitoring

Monitoring ATP5F1 function could help evaluate treatment efficacy in clinical trials[@koopman2013]. Techniques include:

ATP synthesis rates in isolated mitochondria
ATP5F1 protein levels in blood cells
Oxidative modifications to ATP5F1[^105]

Animal Models

Transgenic Mouse Models

Several mouse models of AD and PD show ATP5F1 dysfunction[^106]. The 3xTg-AD mouse model exhibits reduced ATP5F1 expression and activity that parallels disease progression[^107]. MPTP and 6-OHDA models of PD also demonstrate ATP5F1 impairment in dopaminergic neurons[^108].

Knockout Studies

Conditional knockout of ATP5F1 in neurons causes progressive neurodegeneration in mice[^109]. These studies confirm that ATP5F1 is essential for neuronal survival and that even partial impairment can cause disease-like phenotypes[^110]. The knockout mice show:

Reduced ATP production in brain tissue
Progressive motor and cognitive deficits
Mitochondrial abnormalities
Neuroinflammation[^111]

Genetic Associations and Variants

ATP5F1 in Neurodegeneration

While mutations in ATP5F1 itself are not a common cause of neurodegenerative diseases, polymorphisms in the gene may modify disease risk or progression[^112]. Studies have identified ATP5F1 variants associated with altered ATP synthase activity and modified susceptibility to AD and PD[^113]. These genetic findings support the importance of ATP5F1 function in neuronal health[^114].

Mitochondrial DNA and ATP5F1

Mitochondrial DNA mutations affecting ATP synthase subunits can cause severe neurodegenerative phenotypes[^115]. Leigh syndrome, a devastating early-onset neurodegenerative disorder, can result from mutations in mitochondrial ATP synthase subunits[^116]. These findings underscore the critical role of ATP5F1 in brain development and function[^117].

References

[Nature Reviews Neuroscience, Mitochondrial DNA repair and neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20413859/)

[DiMauro S, Schon EA, Mitochondrial respiratory-chain diseases (2003)](https://pubmed.ncbi.nlm.nih.gov/12872256/)

[Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006)](https://pubmed.ncbi.nlm.nih.gov/17005044/)

[Schapira AH, Mitochondrial disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16714302/)

[Wallace DC, A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer (2005)](https://pubmed.ncbi.nlm.nih.gov/15601560/)

[Boyer PD, The binding change mechanism for ATP synthase (1993)](https://pubmed.ncbi.nlm.nih.gov/9169586/)

[Abrahams JP, Leslie AG, Walker JE, Structure at 2.8 A resolution of F1-ATPase from bovine heart mitochondria (1994)](https://pubmed.ncbi.nlm.nih.gov/8206838/)

[Allison WS, F1-ATPase: a highly efficient rotary ATP machine (1998)](https://pubmed.ncbi.nlm.nih.gov/9632706/)

[Weber J, Senior AE, Catalytic mechanism of F-ATPases (2001)](https://pubmed.ncbi.nlm.nih.gov/11255087/)

[Capaldi RA, Aggeler R, Turina P, Wilkens S, Coupling between catalytic sites of F1-ATPase (1994)](https://pubmed.ncbi.nlm.nih.gov/7937835/)

[Boyer PD, Energy, aging, and the F-ATPases (1999)](https://pubmed.ncbi.nlm.nih.gov/10419568/)

[Junge W, Sollra H, ATP synthase: a rotary molecular motor (2000)](https://pubmed.ncbi.nlm.nih.gov/11521061/)

[Noji H, Yasuda R, Yoshida M, Kinosita K, Direct observation of the rotation of F1-ATPase (1997)](https://pubmed.ncbi.nlm.nih.gov/9389891/)

[Vik SB, Antonio BJ, A mechanism of proton translocation by F1F0 ATP synthases (1994)](https://pubmed.ncbi.nlm.nih.gov/8141585/)

[Brand MD, Nicholls DG, Assessing mitochondrial dysfunction in cells (2011)](https://pubmed.ncbi.nlm.nih.gov/21527772/)

[Bernardi P, Krausz F, Forte M, The mitochondrial permeability transition pore (2001)](https://pubmed.ncbi.nlm.nih.gov/11408252/)

UniProt, ATP5F1 - ATP synthase subunit beta, mitochondrial (2026)

[Bianchet MA, Hullihen J, Pedersen PL, Amzel LM, The 2.8-A structure of rat liver F1-ATPase (1998)](https://pubmed.ncbi.nlm.nih.gov/9624142/)

[Kagawa R, Montgomery MG, Braig K, Leslie AG, Walker JE, The structure of bovine F1-ATPase inhibited by ADP and beryllium fluoride (2004)](https://pubmed.ncbi.nlm.nih.gov/15522864/)

[Zhou JM, Boyer PD, Evidence that elongation factor epsilon binding to the beta subunit of chloroplast coupling factor 1 is driven by ATP synthesis (1993)](https://pubmed.ncbi.nlm.nih.gov/7683250/)

[Walker JE, Saraste M, Runswick MJ, Gay NJ, Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold (1982)](https://pubmed.ncbi.nlm.nih.gov/6283630/)

[Boyer PD, The ATP synthase: a splendid molecular machine (1997)](https://pubmed.ncbi.nlm.nih.gov/9329968/)

[Bossy-Wetzel E, Schwarz MM, Green DR, Apoptosis, autophagy and mitochondrial function (2003)](https://pubmed.ncbi.nlm.nih.gov/14568038/)

[Van Laar VS, Berman SB, Mitochondrial dynamics in neurodegeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/19145241/)

[Zhou L, Vale RD, Actin cytoskeleton. Cell mechanics (2010)](https://pubmed.ncbi.nlm.nih.gov/20493179/)

Kann O, Kuhlkamp T, The mitochondrial Na+/Ca2+ exchanger: a potential target for neuroprotection (2015)

[Allaman I, Belanger M, Magistretti PJ, Astrocyte-neuron metabolic relationships (2011)](https://pubmed.ncbi.nlm.nih.gov/21353466/)

[Sheng ZH, Cai Q, Mitochondrial transport in neurons (2012)](https://pubmed.ncbi.nlm.nih.gov/22727456/)

[Devine MJ, Kittler JT, Mitochondria at the neuronal synapse (2018)](https://pubmed.ncbi.nlm.nih.gov/29358859/)

[Kann O, Kovacs R, Mitochondria and neuronal activity (2007)](https://pubmed.ncbi.nlm.nih.gov/17287256/)

[Bolanos JP, Almeida A, Moncada S, Metabolic remodeling in astrocytes (2010)](https://pubmed.ncbi.nlm.nih.gov/20159591/)

[Harris JJ, Jolivet R, Attwell D, Synaptic energy use and supply (2012)](https://pubmed.ncbi.nlm.nih.gov/22890866/)

[Rangaraju V, Calloway NR, Ryan TA, Activity-driven local ATP synthesis is required for synaptic function (2014)](https://pubmed.ncbi.nlm.nih.gov/25432123/)

[Mnatsakanyan N, Jonas EA, The new role of F1F(o) ATP synthase in mitochondria-mediated neurodegeneration and neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32653453/)

Zhou L, McKenzie S, Ecimer M, ATP synthase and the rotary mechanism (2017)

[Hinkle PC, P/O ratios of oxidative phosphorylation (2005)](https://pubmed.ncbi.nlm.nih.gov/15617163/)

[Brown GC, Control of respiration and ATP synthesis in higher eukaryotes (1995)](https://pubmed.ncbi.nlm.nih.gov/8528301/)

[Nicholls DG, Mitochondria and glutamate excitotoxicity (2008)](https://pubmed.ncbi.nlm.nih.gov/18647645/)

[Baughman JM, Perocchi F, Girgis HS, Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter (2011)](https://pubmed.ncbi.nlm.nih.gov/21725308/)

[McCormack JG, Halestrap AP, Denton RM, Role of calcium ions in regulation of mammalian intramitochondrial metabolism (1990)](https://pubmed.ncbi.nlm.nih.gov/1699422/)

[Duchen MR, Mitochondria and calcium: from cell signalling to cell death (2000)](https://pubmed.ncbi.nlm.nih.gov/10692365/)

[Crompton M, The mitochondrial permeability transition pore and its role in cell death (1999)](https://pubmed.ncbi.nlm.nih.gov/10495934/)

[Bernardi P, Rasola A, Forte M, Lippe G, The mitochondrial permeability transition pore: channel formation by F-ATP synthase (2015)](https://pubmed.ncbi.nlm.nih.gov/25790421/)

[Ebanks B, Chakrabarti L, Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurogenerative Diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35237666/)

Kim J, Kim KY, Mincks J, Johnston SM, Im MJ, Phosphorylation of mitochondrial proteins in the heart (2008)

Wu D, Zhu MX, Role of tyrosine phosphorylation in mitochondrial function (2007)

[Hopper RK, Carroll S, Aponte AM, Mitochondrial matrix phosphoproteome (2006)](https://pubmed.ncbi.nlm.nih.gov/16549056/)

[Hojlund K, Bowen BP, Hwang H, In vivo phosphoproteomics (2009)](https://pubmed.ncbi.nlm.nih.gov/19168445/)

[Zhao X, Leon IR, Bak S, Phosphoproteomics of human brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21349321/)

[Deng H, Dodson MW, Huang H, Guo M, The Parkinson's disease protein alpha-synuclein (2008)](https://pubmed.ncbi.nlm.nih.gov/18618002/)

[Hirschey MD, Shimazu T, Goetzman E, SIRT3 regulates mitochondrial protein acetylation (2010)](https://pubmed.ncbi.nlm.nih.gov/20171928/)

[Lombard DB, Alt FW, Cheng HL, Mammalian Sir2 proteins and aging (2007)](https://pubmed.ncbi.nlm.nih.gov/17347643/)

[Someya S, Yu W, Hall WC, Sirt3 mediates the mitochondrial antioxidant response (2010)](https://pubmed.ncbi.nlm.nih.gov/20944083/)

Hirschey MD, SIRT3 regulates mitochondrial function (2011)

[Van de Ven RA, Santos D, Haigis MC, Mitochondrial sirtuins and their functions in the brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28327459/)

Chen J, Martinez J, Cantu-Medrano N, Mitochondrial oxidative stress and Alzheimer disease (2017)

[Murphy MP, How mitochondria produce reactive oxygen species (2009)](https://pubmed.ncbi.nlm.nih.gov/19138737/)

[Federico A, Cardaioli E, Da Pozzo P, Mitochondria, oxidative stress and neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22678057/)

[Manczak M, Anekonda TS, Henson E, Mitochondria are a direct site of A beta toxicity (2006)](https://pubmed.ncbi.nlm.nih.gov/16777400/)

[Reddy PH, Mitochondrial dysfunction in aging and Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/20413857/)

[Manczak M, Park BS, Jung Y, Reddy PH, Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15886045/)

[Swerdlow RH, Mitochondria in Alzheimer brains (2014)](https://pubmed.ncbi.nlm.nih.gov/24269564/)

[Fang D, Wang Y, Zhang Z, Mitochondrial dysfunction in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32445547/)

[Sultana R, Butterfield DA, Redox proteomics studies of oxidized brain proteins in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27181034/)

[Chen X, Yan SD, Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16828058/)

[Reed T, Perluigi M, Sultana R, Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain (2008)](https://pubmed.ncbi.nlm.nih.gov/18408649/)

[Kim SH, Vlkolinsky R, Cairns N, The reduction of NADH ubiquinone oxidoreductase (complex I) activity in Alzheimer's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10702352/)

[Selkoe DJ, Alzheimer's disease is a synaptic failure (2002)](https://pubmed.ncbi.nlm.nih.gov/12445590/)

[Reddy PH, Beal MF, Amyloid beta, mitochondrial dysfunction and synaptic loss (2008)](https://pubmed.ncbi.nlm.nih.gov/18631949/)

[Aleardi AM, Benard G, Augereau O, Amyloid-beta peptide directly induces mitochondrial dysfunction (2005)](https://pubmed.ncbi.nlm.nih.gov/15809120/)

[Wang X, Su B, Zheng L, The role of mitochondrial dynamics in Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19119293/)

[Cheng Y, Bai F, The association of tau with mitochondrial dysfunction in Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29348201/)

[Du H, Guo L, Yan SS, Synaptic mitochondrial pathology in Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22207184/)

[Schapira AH, Cooper JM, Dexter D, Mitochondrial complex I deficiency in Parkinson's disease (1990)](https://pubmed.ncbi.nlm.nih.gov/2699284/)

[Keeney PM, Xie J, Capaldi RA, Bennett JP, Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits (2004)](https://pubmed.ncbi.nlm.nih.gov/14749477/)

[Exner N, Lutz AK, Haass C, Winklhofer KF, Mitochondrial dysfunction in Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22710126/)

[Van Laar VS, Dukes AA, Cascio M, Berman SB, Mitochondrial dysfunction in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29760404/)

[Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT, What causes the death of dopaminergic neurons in Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/21838479/)

[Devi L, Anandatheerthavarada HK, Mitochondrial targeting of a toxic alpha-synuclein mutant (2009)](https://pubmed.ncbi.nlm.nih.gov/19586926/)

[Liu G, Zhang C, Yin J, alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions (2009)](https://pubmed.ncbi.nlm.nih.gov/19369547/)

[Poehler AM, Xiang W, Spitzer P, Autophagy modulates alpha-synuclein inclusion formation in response to mitochondrial damage (2014)](https://pubmed.ncbi.nlm.nih.gov/24389368/)

[Ryan T, Bamm VV, Stykel MG, Co-expression of alpha-synuclein at synapses leads to mitochondrial dysfunction and altered synaptic vesicle trafficking (2015)](https://pubmed.ncbi.nlm.nih.gov/25849425/)

[Bellucci A, Zaltieri M, Missale C, From alpha-synuclein to synaptic dysfunction in Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22814749/)

[Pissadaki EK, Bolam JP, The energy cost of action potential propagation in dopamine neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/17656431/)

[Surmeier DJ, Schumacker PT, Guzman JD, Calcium, AMPK, and oxidative stress in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23774265/)

[Grunewald A, Kumar KR, Sue CM, New insights into the complex role of mitochondria in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30656164/)

[Onyango IG, Dennis P, Khan SM, Mitochondrial dysfunction in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27105852/)

[Cocco S, Rinaudo M, Fusco S, Mitochondrial involvement in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31744049/)

[Mattson MP, Gleichmann M, Cheng A, Mitochondria in neuroplasticity and neurological disorders (2008)](https://pubmed.ncbi.nlm.nih.gov/19021227/)

[Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (1997)](https://pubmed.ncbi.nlm.nih.gov/11746717/)

Liu J, Wang X, Shao Y, Coenzyme Q10 in Alzheimer's disease (2008)

Someya S, Yamasoba T, Weindruch R, Sirt3 mediates the anti-aging effects of caloric restriction (2009)

[Chaturvedi RK, Beal MF, Mitochondrial approaches for neuroprotection (2008)](https://pubmed.ncbi.nlm.nih.gov/18618005/)

Van Laar VS, Berman SB, Mitochondrial dynamics in neurodegeneration (2009)

[Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E, Mitochondrial fragmentation in neurodegeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/18344978/)

[Armstrong JS, Mitochondrial medicine (2006)](https://pubmed.ncbi.nlm.nih.gov/17015847/)

Orsucci D, Mancuso M, Filosto M, Mitochondrial diseases and mitochondrial dysfunction in neurodegenerative disorders (2010)

[Moreira PI, Carvalho C, Zhu X, Mitochondrial dysfunction is a trigger of Alzheimer's disease pathogenesis (2010)](https://pubmed.ncbi.nlm.nih.gov/20080842/)

Zhang J, Niu H, Huang J, Association between ATP5F1 polymorphisms and Alzheimer's disease (2015)

[Gaweda-Walerych K, Safranow K, Maruszak A, Mitochondrial complex I genes and Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20222178/)

[Bi R, Zhang J, Yu M, Mitochondrial DNA haplogroups and Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24981858/)

[Schon EA, Bonilla E, DiMauro S, Mitochondrial DNA mutations and pathogenesis (2007)](https://pubmed.ncbi.nlm.nih.gov/17486096/)

[Lake NJ, Compton AG, Rahman S, Thorburn DR, Leigh syndrome: One disorder, more than 75 monogenic causes (2016)](https://pubmed.ncbi.nlm.nih.gov/26662268/)

[Koopman WJ, Distelmaier F, Smeitink JA, Willems PH, OXPHOS mutations and neurodegeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/23580933/)

Pathway Diagram

The following diagram shows the key molecular relationships involving ATP5F1 — ATP Synthase F1 Subunit Beta discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

ATP5F1 — ATP Synthase F1 Subunit Beta

ATP5F1 — ATP Synthase F1 Subunit Beta

ATP5F1 — ATP Synthase F1 Subunit Beta

Pathway / Mechanism Diagram

ATP5F1 — ATP Synthase F1 Subunit Beta

ATP5F1 — ATP Synthase F1 Subunit Beta

Pathway / Mechanism Diagram

Overview

Molecular Mechanism of ATP Synthesis

The Binding Change Mechanism

Rotary Catalysis and Energy Coupling

Structure of the ATP5F1 Protein

Function in Brain Mitochondria

Mitochondrial Localization and Structure

Expression in Different Brain Cell Types

Role in Neuronal Energy Metabolism

Oxidative Phosphorylation in Neurons

Coupling Efficiency and Proton Gradient

Calcium and Energy Metabolism

Post-Translational Modifications

Phosphorylation

Acetylation and SIRT3

Oxidative Modifications

Dysfunction in Alzheimer's Disease

Reduced ATP5F1 Expression and Activity

Oxidative Stress and ATP5F1

Relationship with Amyloid-Beta and Tau

Dysfunction in Parkinson's Disease

Mitochondrial Complex I and ATP Synthase

Alpha-Synuclein and Mitochondrial Function

Energy Crisis in Dopaminergic Neurons

Therapeutic Approaches

Small Molecule Activators

Gene Therapy Approaches

Mitochondrial Protection Strategies

Biomarkers

ATP5F1 as a Biomarker

Therapeutic Monitoring

Animal Models

Transgenic Mouse Models

Knockout Studies

Genetic Associations and Variants

ATP5F1 in Neurodegeneration

Mitochondrial DNA and ATP5F1

See Also

References

Pathway Diagram